Sarah Davis
MPhys
School of Health and Related Research
Senior Lecturer in Health Economics
s.davis@sheffield.ac.uk
+44 114 222 5209
+44 114 222 5209
+44 114 222 0749
(Fax)
1011, Regent Court (ScHARR)
Full contact details
Sarah Davis
School of Health and Related Research
1011
Regent Court (ScHARR)
30 Regent Street
Sheffield
S1 4DA
School of Health and Related Research
1011
Regent Court (ScHARR)
30 Regent Street
Sheffield
S1 4DA
- Profile
-
I have over 15 years experience in developing health economic models to evaluate the cost-effectiveness of healthcare interventions including diagnostic tests, risk-assessment tools, and both pharmacological and non-pharmacological treatments. I work primarily on NICE technology appraisals and research projects funded by the NIHR HTA programme. I am a member of ScHARR-TAG and I was the Deputy Director of the NICE Decision Support Unit (DSU) from January 2010 to March 2022
I previously spent three years as the Senior Health Economist at the National Collaborating Centre for Nursing and Supportive Care which developed Clinical Guidelines for NICE. When this centre was merged with three others to form the National Clinical Guideline Centre (NCGC) in April 2009, I joined the NCGC as Health Economics Lead. Prior to this, I was a cost-effectiveness modeller within the HEDS section at ScHARR from 2004 to 2006.
- Research interests
-
My research interests are cost-effectiveness modelling, technology appraisal, and clinical guideline development.
Current projects
- The cost-effectiveness of venous thromboembolism risk assessment tools for hospital inpatients - NIHR127454
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- Decision‐analysis modelling of the effects of thromboprophylaxis for people with lower limb immobilisation for injury. British Journal of Haematology, 186(1), 166-168. View this article in WRRO
- Should cost effectiveness analyses for NICE always consider future unrelated medical costs?. BMJ, 359. View this article in WRRO
- Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study. PharmacoEconomics, 35(5), 561-573. View this article in WRRO
- A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technology Assessment, 20(78), 1-406. View this article in WRRO
- VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS. International Journal of Technology Assessment in Health Care, 30(3), 312-324. View this article in WRRO
- The cost-effectiveness of multi-component interventions to prevent delirium in older people undergoing surgical repair of hip fracture.. Eur J Orthop Surg Traumatol, 24(2), 187-195.
- A review of the psychometric performance of the EQ-5D in people with urinary incontinence.. Health Qual Life Outcomes, 11, 20. View this article in WRRO
- Tilt testing is more cost-effective than implantable loop recorder monitoring as a means of directing pacing therapy in people with recurrent episodes of suspected vasovagal syncope that affect their quality of life or present a high risk of injury.. Heart, 99(11), 805-810.
- Implantable loop recorders are cost-effective when used to investigate transient loss of consciousness which is either suspected to be arrhythmic or remains unexplained.. Europace, 14(3), 402-409.
- Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration.. Eye (Lond), 21(12), 1455-1463.
All publications
Journal articles
- Assessing the effectiveness of bisphosphonates for the prevention of fragility fractures : an updated systematic review and network meta‐analyses. JBMR Plus.
- A clinical tool to identify older women with back pain at high risk of osteoporotic vertebral fractures (Vfrac) : a population-based cohort study with exploratory economic evaluation. Age and Ageing, 51(3).
- Comparing medication adherence in patients receiving bisphosphonates for preventing fragility fractures: a comprehensive systematic review and network meta-analysis. Osteoporosis International.
- Utility of PINP to monitor osteoporosis treatment in primary care, the POSE study (PINP and Osteoporosis in Sheffield Evaluation). Bone, 158.
- Which is the best model to assess risk for venous thromboembolism in hospitalised patients?. BMJ, 373, n1106.
- Vfrac – a simple clinical tool that identifies older women with back pain at high risk of osteoporotic vertebral fractures. Bone Reports, 14, 100958.
- Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation. Health Technology Assessment, 24(46). View this article in WRRO
- Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. Health Technology Assessment, 24(29). View this article in WRRO
- Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures : a systematic review and network meta-analysis. Bone, 130. View this article in WRRO
- Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation. Health Technology Assessment, 23(63), 1-190. View this article in WRRO
- An observational cohort study to produce and evaluate an improved tool to screen older women with back pain for osteoporotic vertebral fractures (Vfrac): study protocol. Archives of Osteoporosis, 14(1). View this article in WRRO
- Thromboprophylaxis in lower limb immobilisation after injury (TiLLI). Emergency Medicine Journal, 0, 1-6. View this article in WRRO
- Decision‐analysis modelling of the effects of thromboprophylaxis for people with lower limb immobilisation for injury. British Journal of Haematology, 186(1), 166-168. View this article in WRRO
- Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.. Pharmacoeconomics. View this article in WRRO
- Open-label, cluster randomised controlled trial and economic evaluation of a brief letter from a GP on unscheduled medical contacts associated with the start of the school year: The PLEASANT trial. BMJ Open, 8(4). View this article in WRRO
- Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(10), 1143-1151. View this article in WRRO
- Should cost effectiveness analyses for NICE always consider future unrelated medical costs?. BMJ, 359. View this article in WRRO
- Validation of a DICE Simulation Against a Discrete Event Simulation Implemented Entirely in Code. PharmacoEconomics, 35(10), 1103-1109. View this article in WRRO
- Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study. PharmacoEconomics, 35(5), 561-573. View this article in WRRO
- PLEASANT: Preventing and Lessening Exacerbations of Asthma in School-age children Associated with a New Term - a cluster randomised controlled trial and economic evaluation.. Health Technology Assessment, 20(93), 1-154. View this article in WRRO
- A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technology Assessment, 20(78), 1-406. View this article in WRRO
- Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis. Bone, 89, 52-58. View this article in WRRO
- Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective. PharmacoEconomics, 33(11), 1187-1194. View this article in WRRO
- Alteplase for the Treatment of Acute Ischaemic Stroke: A NICE Single Technology Appraisal; an Evidence Review Group Perspective. PharmacoEconomics, 33(3), 225-233. View this article in WRRO
- Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results. Value in Health, 17(8), 762-771. View this article in WRRO
- VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS. International Journal of Technology Assessment in Health Care, 30(3), 312-324. View this article in WRRO
- The cost-effectiveness of multi-component interventions to prevent delirium in older people undergoing surgical repair of hip fracture.. Eur J Orthop Surg Traumatol, 24(2), 187-195.
- Correction. Heart, 100(4), 350-350.
- Preventing and lessening exacerbations of asthma in school-age children associated with a new term (PLEASANT): Study protocol for a cluster randomised control trial. Trials, 14(1). View this article in WRRO
- Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal.. Pharmacoeconomics, 31(8), 653-661.
- A review of the psychometric performance of the EQ-5D in people with urinary incontinence.. Health Qual Life Outcomes, 11, 20. View this article in WRRO
- Transient loss of consciousness: Summary of NICE guidance. Heart.
- Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.. Age Ageing, 42(1), 14-20.
- Tilt testing is more cost-effective than implantable loop recorder monitoring as a means of directing pacing therapy in people with recurrent episodes of suspected vasovagal syncope that affect their quality of life or present a high risk of injury.. Heart, 99(11), 805-810.
- The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.. Health Technol Assess, 16(21), 1-470.
- Implantable loop recorders are cost-effective when used to investigate transient loss of consciousness which is either suspected to be arrhythmic or remains unexplained.. Europace, 14(3), 402-409.
- Guidelines Transient loss of consciousness-initial assessment, diagnosis, and specialist referral: summary of NICE guidance. BRIT MED J, 341.
- A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.. Health Technol Assess, 12(27), iii-124.
- Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration.. Eye (Lond), 21(12), 1455-1463.
- Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.. Health technology assessment (Winchester, England), 11(7).
- The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.. Health Technol Assess, 11(4), 1-134.
- Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.. Health Technol Assess, 11(40), 1-144.
- Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.. Health Technol Assess, 11(7), iii-231.
- The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease.. Value Health, 10(1), 32-41.
- The hospitalisation costs and out-patient costs of fragility fractures. Women's Health Medicine, 3(4), 149-151.
- A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.. Health Technol Assess, 9(22), 1-160. View this article in WRRO
- Risk assessment models for venous thromboembolism in pregnancy and in the puerperium: a systematic review. BMJ Open.
- Corrigendum: A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technology Assessment, 20(78), 407-424. View this article in WRRO
- A systematic review and economic evaluation of exercise referral schemes in primary care: a short report. Health Technology Assessment, 19(60), 1-110. View this article in WRRO
Conference proceedings papers
- Monitoring Bisphosphonate Treatment In Primary Care: PINP And Osteoporosis In Sheffield Evaluation (POSE Study). JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 37 (pp 64-65)
- Addition of symptoms to traditional risk factors improves prediction of those at high risk of vertebral fractures: Results of the Vfrac study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 37 (pp 60-60)
- ASSESSING THE EFFECTIVENESS OF BISPHOSPHONATES FOR THE PREVENTION OF FRAGILITY FRACTURES: AN UPDATED SYSTEMATIC REVIEW AND NETWORK META-ANALYSES. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S270-S270)
- MONITORING BISPHOSPHONATE TREATMENT IN PRIMARY CARE: PINP AND OSTEOPOROSIS IN SHEFFIELD EVALUATION (POSE STUDY). OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S288-S288)
- LATE-BREAKING ABSTRACT: PLEASANT: Preventing and lessening exacerbations of asthma in school-age children associated with a new term. 1.6 General Practice and Primary Care
- VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMOURS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS. VALUE IN HEALTH, Vol. 16(7) (pp A327-A327)
- Economic evaluation of the use of lanthanum carbonate from an Australian perspective. NEPHROLOGY DIALYSIS TRANSPLANTATION, Vol. 22 (pp 186-186)
- Lanthanum carbonate for the treatment of hyperphosphataemia: Development of a cost effectiveness model. VALUE HEALTH, Vol. 7(6) (pp 805-805)
Reports
- Decision‐analysis modelling of the effects of thromboprophylaxis for people with lower limb immobilisation for injury. British Journal of Haematology, 186(1), 166-168. View this article in WRRO
- Teaching interests
-
My teaching interests include decision modelling in health care and supporting non-health economists to engage with health economic evidence when developing guidance for the NHS.
- Professional activities
-
Member of NICE Highly Specialised Technologies Evaluation Committee